BACKGROUND/AIMS: The mouse mdr2 gene encodes a P-glycoprotein expressed in the canalicular membrane of the hepatocyte. Mice in which this gene has been inactivated (mdr2 -/-) show a defect in biliary phospholipid and cholesterol secretion and develop non-suppurative cholangitis. We hypothesized that secretion of bile salts without lipids initiates this liver disease. METHODS: To delineate the pathologic process, mdr2 (-/-) mice were fed different bile salt-supplemented diets for 22 weeks after weaning. Aspects of liver pathology including eosinophilic bodies, portal inflammation, ductular proliferation, mitotic activity and fibrosis were semi-quantitatively scored. RESULTS: It was observed that liver pathology was more severe in female than in male mice when fed a purified control diet. This correlated with a more hydrophobic bile salt composition of female vs. male bile. When increasing amounts of cholate were added to the diet (0.01% and 0.1%), the secretion of taurocholate increased and this was accompanied by a more severe liver pathology. At the high dose of cholate (0.1%), the bile salt compositions of male and female mice became similar, as did the severity of the histological score. Addition of cholate to the diet did not induce liver pathology in (+/+) mice. Addition of ursodeoxycholate to the diet (0.5%) led to a near complete replacement of biliary bile salts by tauroursodeoxycholate and this reduced pathology and dissipated the difference between males and females. CONCLUSIONS: These observations support our hypothesis that liver pathology in the mdr2 (-/-) mouse is caused by bile salts and depends on the hydrophobicity c.q. cytotoxicity of biliary bile salts.
BACKGROUND/AIMS: The mousemdr2 gene encodes a P-glycoprotein expressed in the canalicular membrane of the hepatocyte. Mice in which this gene has been inactivated (mdr2 -/-) show a defect in biliary phospholipid and cholesterol secretion and develop non-suppurative cholangitis. We hypothesized that secretion of bile salts without lipids initiates this liver disease. METHODS: To delineate the pathologic process, mdr2 (-/-) mice were fed different bile salt-supplemented diets for 22 weeks after weaning. Aspects of liver pathology including eosinophilic bodies, portal inflammation, ductular proliferation, mitotic activity and fibrosis were semi-quantitatively scored. RESULTS: It was observed that liver pathology was more severe in female than in male mice when fed a purified control diet. This correlated with a more hydrophobic bile salt composition of female vs. male bile. When increasing amounts of cholate were added to the diet (0.01% and 0.1%), the secretion of taurocholate increased and this was accompanied by a more severe liver pathology. At the high dose of cholate (0.1%), the bile salt compositions of male and female mice became similar, as did the severity of the histological score. Addition of cholate to the diet did not induce liver pathology in (+/+) mice. Addition of ursodeoxycholate to the diet (0.5%) led to a near complete replacement of biliary bile salts by tauroursodeoxycholate and this reduced pathology and dissipated the difference between males and females. CONCLUSIONS: These observations support our hypothesis that liver pathology in the mdr2 (-/-) mouse is caused by bile salts and depends on the hydrophobicity c.q. cytotoxicity of biliary bile salts.
Authors: Jeannie Chan; Michael C Mahaney; Rampratap S Kushwaha; Jane F VandeBerg; John L VandeBerg Journal: J Lipid Res Date: 2010-05-20 Impact factor: 5.922
Authors: Cindy Kunne; Marijke de Graaff; Suzanne Duijst; Dirk R de Waart; Ronald P J Oude Elferink; Coen C Paulusma Journal: Lab Invest Date: 2014-07-28 Impact factor: 5.662
Authors: Alexander G Miethke; Wujuan Zhang; Julia Simmons; Amy E Taylor; Tiffany Shi; Shiva Kumar Shanmukhappa; Rebekah Karns; Shana White; Anil G Jegga; Celine S Lages; Stephenson Nkinin; Bradley T Keller; Kenneth D R Setchell Journal: Hepatology Date: 2015-08-21 Impact factor: 17.425
Authors: Renxue Wang; Jonathan A Sheps; Lin Liu; Jun Han; Patrick S K Chen; Jason Lamontagne; Peter D Wilson; Ian Welch; Christoph H Borchers; Victor Ling Journal: J Lipid Res Date: 2018-11-11 Impact factor: 5.922
Authors: Katrin Hochrath; Sabrina Ehnert; Cheryl L Ackert-Bicknell; Yvonne Lau; Andrea Schmid; Marcin Krawczyk; Jan G Hengstler; Jordanne Dunn; Kanishka Hiththetiya; Birgit Rathkolb; Kateryna Micklich; Wolfgang Hans; Helmut Fuchs; Valérie Gailus-Durner; Eckhard Wolf; Martin Hrabě de Angelis; Steven Dooley; Beverly Paigen; Britt Wildemann; Frank Lammert; Andreas K Nüssler Journal: Bone Date: 2013-03-29 Impact factor: 4.398
Authors: B L Vaisman; G Lambert; M Amar; C Joyce; T Ito; R D Shamburek; W J Cain; J Fruchart-Najib; E D Neufeld; A T Remaley; H B Brewer; S Santamarina-Fojo Journal: J Clin Invest Date: 2001-07 Impact factor: 14.808
Authors: James H Tabibian; Slobodan I Macura; Steven P O'Hara; Jeff L Fidler; James F Glockner; Naoki Takahashi; Val J Lowe; Bradley J Kemp; Prasanna K Mishra; Pamela S Tietz; Patrick L Splinter; Christy E Trussoni; Nicholas F LaRusso Journal: Lab Invest Date: 2013-04-15 Impact factor: 5.662